George Pentheroudakis (born 3/12/1967) holds an MD degree from the Aristotle University of Thessaloniki, Greece (1991). He specialized in Internal Medicine in Thessaloniki, Greece (1993-1999). Subsequently he trained in Medical Oncology at the Beatson Oncology Centre, Glasgow, United Kingdom (1999-2002) where he gained experience in the development of Phase I-III clinical trials at the Beatson Oncology Center Clinical Trials Unit, working for Professors S Kay, J Cassidy, C Twelves, J Evans.
Returning to Greece, he has developed his PhD thesis on mechanisms of neutrophil production of surface mucoglycoproteins from GCSF stimulation and successfully defended it in 2006. He has worked as a Consultant Medical Oncologist at the Department of Medical Oncology, University of Ioannina, Greece, since 2003. He served as Chair of the Scientific Committee of the Hellenic Cooperative Oncology Group (HeCOG) from 2012 to 2016.
Currently he serves as Professor of Oncology at the Medical School, University of Ioannina and is Head of the Medical Oncology Department, in which he founded a Translational and Clinical Research Unit, a Palliative and Supportive Care Unit. He spearheaded its admission in the EORTC GI Working Group and its designation as an ESMO Centre of Excellence for Integrated Oncology. He has regular teaching duties at the Medical School and is supervising several PhD students in University of Ioannina laboratories. He is actively involved in translational research in cancer and in early phase I-II studies evaluating novel agents in collaboration with national and international groups. He is investigating liquid biopsy research applications in gastrointestinal malignancies in the context of the Liquid Biopsy Unit, Dept of Clinical Chemistry, University of Ioannina, founded in 2017. He coordinates the GI Working Group of HeCOG and is the coordinating investigator of several non-commercial investigator-initiated national clinical trials. His main research interests are gastrointestinal cancer, cancer of unknown primary, translational cancer research (with emphasis on angiogenesis, signal transduction, pro metastatic signatures, malignant clonal evolution, liquid biopsies) and new drug development.
Dr. Pentheroudakis serves as Chair of the ESMO Guidelines Committee (2016-2019), leading a team of experts who produce multidisciplinary, widely used clinical practice guidelines (more than 1.5 million web downloads annually) and is a member of the ESMO Council (2019 to date). In the past he served as a Member of the Executive Board (2016-2018), ESMO CUP and Endocrine Tumour Faculty Coordinator, ESMO Guidelines Working Group Subject Editor and Co-Chair. He is also a member of the American Society of Clinical Oncology (ASCO) and is actively involved in different medical journal editorial boards including Cancers, Cancer Treatment Communications, EJSO - European Journal of Surgical Oncology, Rare Cancers and Therapy, ESMO Open. He has (co)-authored 256 PubMed-indexed peer-reviewed papers and speaks English, French and Italian.